Overall, inhibiting VEGF in the course of cervical cancer is more successful than inhibiting VEGF in ovarian cancer; in other words, bevacizumab has a higher inhibitory effect on cervical cancer than ovarian cancer (109). Here, VEGFA is linked to cervical carcinoma.